Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company developing genetic medicines for diseases involving targets inside cells. Its proprietary Endosomal Escape Vehicle (EEV) platform is designed to deliver therapeutic molecules into cells; its lead programs pair EEV peptides with… From the company’s description.
Over the twelve months to Sep 30, 2026, Entrada Therapeutics, Inc. reported revenue of $3.98M, down 93.5% from a year earlier, and a net loss of $161.39M. Operations used $136.32M in cash. In fiscal 2025, it reported revenue of $25.42M, down 87.9% from fiscal 2024, and a net loss of $143.75M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Entrada Therapeutics, Inc. does
In the company’s own words
Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company developing genetic medicines for diseases involving targets inside cells. Its proprietary Endosomal Escape Vehicle (EEV) platform is designed to deliver therapeutic molecules into cells; its lead programs pair EEV peptides with oligonucleotides to address neuromuscular diseases, especially Duchenne muscular dystrophy (DMD). Clinical-stage DMD candidates ENTR-601-44, ENTR-601-45 and ENTR-601-50 target distinct mutations through exon skipping, while ENTR-601-51 is advancing toward clinical studies. Entrada also supports Vertex Pharmaceuticals’ development of VX-670, an EEV-based candidate for myotonic dystrophy type 1, under a global collaboration in which Vertex holds an exclusive license and leads development, manufacturing and commercialization. In ocular disease, the company is developing oligonucleotide-based programs, including ENTR-801 for Usher syndrome type 2A. Its pipeline spans clinical and preclinical programs, with no reportable business segments described. Its website is www.entradatx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1689375
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Entrada Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Entrada Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Entrada Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Entrada Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Entrada Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”